(0641–0670) Systemic Lupus Erythematosus – Treatment Poster I

Sunday, October 26, 2025

10:30 AM - 12:30 PM Central Time

Location: Hall F1

CE: 0.00

Presentations:

10:30 AM - 12:30 PM Central Time

A-319, a CD3×CD19 T Cell Engager, for the Treatment of Refractory Systemic Lupus Erythematosus: Preliminary Evidence of Autoimmune Reset
Abstract Poster Presenter: Qiubai Li, MD – Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
10:30 AM - 12:30 PM Central Time

Achievement of Low Disease Activity and Remission in Patients with Systemic Lupus Erythematosus Treated with Dapirolizumab Pegol: 48-week Results from a Phase 3 Trial
Abstract Poster Presenter: Maria Dall'Era, MD – UCSF
10:30 AM - 12:30 PM Central Time

anti-cd19 Chimeric Antigen Receptor T Cell Therapy for Refractory Systemic Lupus Erythematosus: An Open-label Pilot Study
Abstract Poster Presenter: Rong Mu, n/a – Peking University Third Hospital
10:30 AM - 12:30 PM Central Time

Belimumab Real-World Effectiveness in Chinese Patients with Systemic Lupus Erythematosus: Interim Analysis of an Ambidirectional, Observational Cohort Study (RELIABLE)
Abstract Poster Presenter: Terry Yan, -None- – GSK
10:30 AM - 12:30 PM Central Time

Belimumab-Based Triple Therapy in Proliferative Lupus Nephritis: Renal Outcomes and Glucocorticoid Tapering in a Real-World Multicenter Cohort
Abstract Poster Presenter: Javier Narvaez, PhD – Hospital Universitario de Bellvitge
10:30 AM - 12:30 PM Central Time

Blood pressure remains elevated in patients initiating voclosporin with low baseline blood pressure: evidence from patients in routine clinical care
Abstract Poster Presenter: Eric Roberts, PhD, MPH – University of California, San Francisco
10:30 AM - 12:30 PM Central Time

Clinical and Laboratory Factors Associated With Biopsy-Confirmed Antimalarial-Induced Cardiomyopathy
Abstract Poster Presenter: Youngmin Kim, MD – Brigham and Women's Hospital
10:30 AM - 12:30 PM Central Time

Clinical Significance of Therapeutic Drug Level Monitoring for Mycophenolate in Patients With Extra-renal Systemic Lupus Erythematosus – A Systematic Review & Meta-analysis
Abstract Poster Presenter: Zahraa Qamhieh, MBBS, MMSc – University of Wisconsin Madison
10:30 AM - 12:30 PM Central Time

Effects of Deucravacitinib on Dysregulated Autoimmune Gene Modules That Correlate With Skin Disease Severity and Treatment Response in Patients With Cutaneous Manifestations of Lupus Erythematosus: Biomarker Results From a Global, Randomized, Placebo-Controlled Phase 2 Study
Abstract Poster Presenter: J. Michelle Kahlenberg, MD, PhD – University of Michigan
10:30 AM - 12:30 PM Central Time

Efficacy Across Baseline Characteristic Subgroups in Patients With Systemic Lupus Erythematosus Treated With Upadacitinib: Results From SLEek, a Phase 2 Randomized
Abstract Poster Presenter: Marta Mosca, MD;PhD – University of Pisa
10:30 AM - 12:30 PM Central Time

Evolution and Readiness: Preparing for Cell Therapy in Lupus Trials, A LuCIN Network Evaluation
Abstract Poster Presenter: Brandon Jackson, MPH – Lupus Therapeutics
10:30 AM - 12:30 PM Central Time

Glucocorticoid-Sparing Effects and Flare Suppression: Metformin Versus SGLT2 Inhibitors in Systemic Lupus Erythematosus
Abstract Poster Presenter: Takeshi Suzuki, n/a (he/him/his) – St. Marianna University School of Medicine
10:30 AM - 12:30 PM Central Time

Human papillomavirus infection and systemic lupus erythematosus under biologic therapy: a retrospective analysis in a multicenter cohort
Abstract Poster Presenter: Ivette Casafont-Sole, MD – Hospital Universitari Germans Trias i Pujol
10:30 AM - 12:30 PM Central Time

Improvement of Fatigue, Musculoskeletal Pain, and Morning Stiffness in Patients with Systemic Lupus Erythematosus Treated with Dapirolizumab Pegol: 48-Week Results from a Phase 3 Trial
Abstract Poster Presenter: Joan Merrill, MD – Oklahoma Medical Research Foundation
10:30 AM - 12:30 PM Central Time

In Vitro Pharmacological Profile of GLPG3667 Suggests Differentiation from the TYK2 Inhibitors Deucravacitinib and Zasocitinib at Their Clinical Dose Regimens
Abstract Poster Presenter: Chantal Tasset, PhD – Galapagos NV
10:30 AM - 12:30 PM Central Time

Infusion-Related Reactions (IRRs) and Hematologic Events Associated With Obinutuzumab in Lupus Nephritis: A Secondary Analysis of a Phase III Trial
Abstract Poster Presenter: Richard Furie, MD – Northwell
10:30 AM - 12:30 PM Central Time

iPSC-Derived Off-the-Shelf anti-CD19 CAR T cells Deliver Improved Clinical Outcomes in Lupus with Reduced or No Conditioning Chemotherapy
Abstract Poster Presenter: Parastoo Fazeli, MD (she/her/hers) – UMN
10:30 AM - 12:30 PM Central Time

Low-dose belimumab reduced disease flares in patients with systemic lupus erythematosus at low disease activity: a multicenter, randomized, double-blind, placebo-controlled trial
Abstract Poster Presenter: Fangfang Sun, MD – Renji Hospital
10:30 AM - 12:30 PM Central Time

Obinutuzumab Demonstrates Steroid-Sparing Effects and Consistent Benefit In Patients with Lupus Nephritis When Using Multiple Primary Endpoint Definitions: A Secondary Analysis of Phase III Trial Results
Abstract Poster Presenter: Brad Rovin, MD – The Ohio State University
10:30 AM - 12:30 PM Central Time

Obinutuzumab Shows Promise in Lupus Nephritis Regardless of Baseline Serological Markers: An Exploratory Post Hoc Analysis of a Phase II Trial
Abstract Poster Presenter: Ed Vital, MD – University of Leeds
10:30 AM - 12:30 PM Central Time

Pharmacodynamic Effects of Obinutuzumab on B cells and Serological Markers in Patients With Active Lupus Nephritis: Results From a Phase III Trial
Abstract Poster Presenter: Richard Furie, MD – Northwell
10:30 AM - 12:30 PM Central Time

Preliminary Analysis Of Open-Label Dose-Titration Phase Of SLE Treatment With N-Acetylcysteine (SNAC) Shows Evidence For Potential Improvement Of SLEDAI, BILAG, ADHD And Fatigue Scores In Patients With Active SLE
Abstract Poster Presenter: FNU Ruchi, MD – SUNY Upstate Medical University
10:30 AM - 12:30 PM Central Time

Real World Comparative Use of Anifrolumab in Systemic Lupus Erythematosus and Cutaneous Lupus Erythematosus: A Multicenter Cohort Study
Abstract Poster Presenter: Sarah Al Qassimi, MD – Cleveland Clinic Abu Dhabi
10:30 AM - 12:30 PM Central Time

Real-world Effectiveness and Usage of Voclosporin: Data from the Enlight-LN Registry
Abstract Poster Presenter: Leanna Wise, MD, MPH – LAGMC/Keck Medicine of USC
10:30 AM - 12:30 PM Central Time

Reported Adverse Events Associated With Systemic Lupus Erythematosus (SLE) Treatment: Insights From the FDA Adverse Event Reporting System (FAERS) 2023
Abstract Poster Presenter: Sarah Crisci, MS, MPH – Thermo Fisher Scientific
10:30 AM - 12:30 PM Central Time

Retrospective Chart Audit Reveals Gaps in Steroid Tapering and Use of ACR Guideline-Recommended Regimens in LN
Abstract Poster Presenter: Sawyer May, BA – Spherix Global Insights
10:30 AM - 12:30 PM Central Time

Safety and efficacy of autologous CD19-CAR T-cell therapy in patients with autoimmune disease - data from the CASTLE Phase I/II basket study
Abstract Poster Presenter: Georg Schett, MD – Uniklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Germany
10:30 AM - 12:30 PM Central Time

The ERβ Agonist, OSU-ERβ-012, Suppresses Systemic, Kidney and Heart Inflammation in a Chimeric Mouse Model of Systemic Lupus Erythematosus
Abstract Poster Presenter: Braden Zeno, BS – Ohio State University
10:30 AM - 12:30 PM Central Time

WITHDRAWN